Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
Phase 3 Completed
546 enrolled 29 charts
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Phase 1/2 Completed
11 enrolled 11 charts
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Phase 2 Completed
83 enrolled 17 charts
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Phase 2 Completed
647 enrolled 17 charts
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
Phase 1/2 Completed
25 enrolled 10 charts
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Phase 2 Completed
46 enrolled 13 charts
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
134 enrolled 12 charts
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Completed
46 enrolled 13 charts
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
Phase 2 Completed
188 enrolled 16 charts
Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
37 enrolled 13 charts
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
55 enrolled 16 charts
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 1/2 Completed
58 enrolled
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase 1/2 Completed
92 enrolled 24 charts
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
29 enrolled
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase 1/2 Completed
136 enrolled 27 charts
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Phase 2 Completed
38 enrolled 10 charts
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Phase 2 Completed
89 enrolled 28 charts
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Phase 2 Completed
56 enrolled 10 charts
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Phase 2 Completed
27 enrolled 8 charts
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Phase 2 Completed
40 enrolled 16 charts
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
69 enrolled 12 charts
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Phase 2 Completed
30 enrolled
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Phase 2 Completed
45 enrolled 18 charts
Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 1 Completed
45 enrolled
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Phase 1 Completed
30 enrolled
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
Phase 2 Completed
56 enrolled 9 charts
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 1/2 Completed
18 enrolled 6 charts
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Phase 2 Completed
143 enrolled 9 charts
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 2 Completed
35 enrolled
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase NA Completed
129 enrolled
Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
Phase 2 Completed
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Phase 1/2 Completed
45 enrolled
Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer
Phase 1 Completed
48 enrolled
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Phase 1 Completed
24 enrolled
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 1 Completed
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
Phase 2 Completed
171 enrolled
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Phase 2 Completed
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase 1/2 Completed
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
95 enrolled
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Phase 2 Completed
78 enrolled
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
Phase 2 Completed
48 enrolled
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
Phase 1 Completed
28 enrolled
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
Phase 2 Completed
40 enrolled
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
Phase 2 Completed
65 enrolled
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Phase 2 Completed
55 enrolled
Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Phase 1 Completed
24 enrolled
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Phase 2 Completed
51 enrolled